GlassScriptPhysician profile
Laura C Cauthen
NPI 1881681880
$2,526.26
in general payments reported to CMS, 2019-2025
30 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $367 · 2021: $456 · 2022: $494 · 2023: $278 · 2024: $367 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $691.64 | 2019-2024 | |
| Astellas Pharma US INC | $258.50 | 2023-2025 | Veozah |
| Abbvie INC. | $250.26 | 2020-2023 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $220.88 | 2019-2025 | |
| Hologic Sales and Service, LLC | $145.66 | 2023-2025 | Acessa Provu System |
| Evofem Biosciences, INC. | $133.86 | 2021-2025 | Phexxi, Solosec, Phexx |
| Meditrina | $129.46 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $105.28 | 2022-2023 | |
| Coopersurgical, INC. | $64.51 | 2019 | |
| Therapeuticsmd, INC. | $52.63 | 2019-2020 | |
| Millicent US INC | $50.18 | 2020-2024 | Intrarosa |
| Myovant Sciences INC. | $43.15 | 2022 | |
| Smith+Nephew, INC. | $37.64 | 2023-2024 | Stravix, Pico 7, Pico 14 |
| Cumberland Pharmaceuticals, INC. | $37.07 | 2022 | |
| Sumitomo Pharma America, INC. | $36.97 | 2023-2025 | Myfembree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.57 | 2019 | |
| Exeltis, USA INC. | $29.08 | 2021 | |
| Organon LLC | $28.16 | 2022-2024 | |
| Aspira Women'S Health INC | $20.91 | 2021-2024 | Ova1 |
| Optumhealth Care Solutions, LLC | $20.17 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Amgen INC. | $19.73 | 2020 | |
| Biogen, INC. | $19.15 | 2024 | |
| Agile Therapeutics, INC. | $19.04 | 2021 | |
| Minerva Surgical, INC | $15.99 | 2024 | |
| Channel Medsystems, INC. | $14.41 | 2023 | |
| Duchesnay USA Incorporated | $13.65 | 2019 | |
| Avion Pharmaceuticals | $13.08 | 2023 | Balcoltra |
| Amag Pharmaceuticals, INC. | $12.95 | 2019 | |
| Virtus Pharmaceuticals LLC | $11.68 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cauthen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.